Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Penel

Showing results (11-20 of 350) with videos related to

Pageof 35
Sort By:
Bulletin Du Cancer|September 5, 2016
[Splicing variant of androgen receptors (AR-V7): New paradigms]Nicolas Penel
Bulletin Du Cancer|October 17, 2017
[Prostate cancer and DNA repair genes]Nicolas Penel
Bulletin Du Cancer|August 2, 2017
[Tyrosine kinase inhibitor as adjuvant treatment of renal cell carcinoma: 1 versus 3]Nicolas Penel
Bulletin Du Cancer|January 24, 2007
[Cancers and pesticides: current data]Nicolas Penel, Damien Vansteene
La Revue Du Praticien|January 12, 2010
[Primary and secondary bone tumors]Nicolas Penel, Mélanie Morel
BMC Medical Research Methodology|July 25, 2012
What does a modified-Fibonacci dose-escalation actually correspond to?Nicolas Penel, Andrew Kramar
Current Opinion in Oncology|July 19, 2016
Inappropriate dose of multitargeted tyrosine kinase inhibitors: the original sinNuria Kotecki, Nicolas Penel
Investigational New Drugs|October 22, 2008
Publication biases and phase II trials investigating anticancer targeted therapiesNicolas Penel, Antoine Adenis
Expert Opinion on Pharmacotherapy|October 22, 2008
Vinorelbine in breast cancerJacques Bonneterre, Nicolas Penel
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 30, 2008
Vancomycin flush as antibiotic prophylaxis for early catheter-related infections: a cost-effectiveness analysisNicolas Penel, Yazdan Yazdanpanah
Pageof 35

Showing results (11-20 of 350) with videos related to

Sort By:
Pageof 35
Bulletin Du Cancer|September 5, 2016
[Splicing variant of androgen receptors (AR-V7): New paradigms]Nicolas Penel
Bulletin Du Cancer|October 17, 2017
[Prostate cancer and DNA repair genes]Nicolas Penel
Bulletin Du Cancer|August 2, 2017
[Tyrosine kinase inhibitor as adjuvant treatment of renal cell carcinoma: 1 versus 3]Nicolas Penel
Bulletin Du Cancer|January 24, 2007
[Cancers and pesticides: current data]Nicolas Penel, Damien Vansteene
La Revue Du Praticien|January 12, 2010
[Primary and secondary bone tumors]Nicolas Penel, Mélanie Morel
BMC Medical Research Methodology|July 25, 2012
What does a modified-Fibonacci dose-escalation actually correspond to?Nicolas Penel, Andrew Kramar
Current Opinion in Oncology|July 19, 2016
Inappropriate dose of multitargeted tyrosine kinase inhibitors: the original sinNuria Kotecki, Nicolas Penel
Investigational New Drugs|October 22, 2008
Publication biases and phase II trials investigating anticancer targeted therapiesNicolas Penel, Antoine Adenis
Expert Opinion on Pharmacotherapy|October 22, 2008
Vinorelbine in breast cancerJacques Bonneterre, Nicolas Penel
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 30, 2008
Vancomycin flush as antibiotic prophylaxis for early catheter-related infections: a cost-effectiveness analysisNicolas Penel, Yazdan Yazdanpanah
Pageof 35